ASCO 2022: Metastatic Breast Cancer Drug Therapy Recap

Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Metastatic Hormone Positive Breast Cancer | 2023 KU Breast Cancer Year in Review Conference

ASCO22 GU Cancer Abstract Overview | Manojkumar Bupathi, MD, MS | 2022 Review and Renew SedonaПодробнее

ASCO22 GU Cancer Abstract Overview | Manojkumar Bupathi, MD, MS | 2022 Review and Renew Sedona

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

ASCO Breast Cancer Update | Jane Meisel, MD | 2022 Review and Renew SedonaПодробнее

ASCO Breast Cancer Update | Jane Meisel, MD | 2022 Review and Renew Sedona

Kidney Cancer Conference Highlights from ASCO 2022Подробнее

Kidney Cancer Conference Highlights from ASCO 2022

2023 Updates In Metastatic Breast Cancer TreatmentПодробнее

2023 Updates In Metastatic Breast Cancer Treatment

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference

Dr. Marleen Kok | San Antonio Breast Cancer Symposium 2022 | Year in ReviewПодробнее

Dr. Marleen Kok | San Antonio Breast Cancer Symposium 2022 | Year in Review

ASCO 2017 RECAP :: The Latest in Colorectal Cancer Research - June 2017 #CRCWebinarПодробнее

ASCO 2017 RECAP :: The Latest in Colorectal Cancer Research - June 2017 #CRCWebinar

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...

NOS ASCO Review 2022 Lung Cancer UpdateПодробнее

NOS ASCO Review 2022 Lung Cancer Update

NOS ASCO Review 2022 Breast Cancer UpdateПодробнее

NOS ASCO Review 2022 Breast Cancer Update

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic TherapyПодробнее

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic Therapy

Breast Cancer HOPA BCOP reviewПодробнее

Breast Cancer HOPA BCOP review